PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are the three biomarkers used clinically to predict the efficacy of ICIs, and these also have a predictive role for the development of irAEs. This evidence concerns the gene CD274 and neoplasm.